India's Piramal Healthcare agreed to buy a portfolio of medical imaging molecules from Germany's Bayer Pharma including one designed to diagnose Alzheimer's that it says could yield $1.5 billion in revenue.
India's Piramal acquires molecular imaging portfolio from Germany's Bayer
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.